
Organization and board members
Hartwig Medical Foundation is an independent foundation partly funded by philanthropy. The foundation has no profit motive and reinvests all acquired funds in achieving its mission. Hartwig Medical Foundation is an independent foundation partly funded by philanthropy. The non-profit foundation reinvests all acquired funds in achieving its mission. Directors Hans van Snellenberg, Edwin Cuppen and Lotte Smits oversee day-to-day management.
Supervisory board
- Constantijn van Oranje-Nassau (chair)
- Rob Defares, founder and Director of IMC
- Guido Derckx, partner at Loyens & Loeff
- Chris Polman, neurologist, represents the Dutch Federation of University Medical Center and chair of the board of Amsterdam UMC’s VUmc location and vicechair of the AMC location
- Emile Voest, internist-oncologist, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, director of Cancer Core Europe
Scientific board
The Scientific Board consists of renowned national and international scientists and advises the Board of Directors and Supervisory Board on scientific and strategic choices, when requested. In addition, the Scientific Board evaluates requests for data for scientific value and feasibility.
- René Bernards, biomedical geneticist, Head of Molecular Carcinogenesis at the Netherlands Cancer Institute – Antoni van Leeuwenhoek, Amsterdam
- Han van Krieken, Rector of the board of Radboud University, Nijmegen
- Bob Löwenberg, hematologist Erasmus MC, Rotterdam
- Roel Verhaak, professor Neurosurgery, Yale School of Medicine, Connecticut (US)
Data Access Board
The Data Access Board consists of a panel of independent experts and reviews data requests for access on legal, social and ethical aspects.
- Ele Visser (chair), founder of the Patient Academy
- Mariska Kool, IT lawyer at The Data Lawyers
- Eline Bunnik, assistent professor Erasmus MC
Employees
Meet our enthusiastic team of lab analysts, bioinformaticians, IT specialists, clinicians and more!


The complete DNA test is an additional tool to help us discover the origin of the cancer in patients with CUP, often enabling us to identify this primary tumor. In addition, the test often reveals new options for targeted treatment.